Antibodies to Watch in a Pandemic (On Demand)

The extraordinary scope and scale of the COVID-19 pandemic has elicited extraordinary responses world-wide. Organizations located across the globe have mobilized teams to research the SARS-CoV-2 virus and COVID-19, conduct clinical studies of repurposed biologics, and research and develop anti-SARS-CoV-2 biologics. Disruptions at companies and regulatory agencies, however, have raised concerns about the effects of the pandemic on possible approvals of non-COVID-19 antibody therapeutics. In a series of webinars, The Antibody Society will report on important developments in the commercial pipeline of antibody therapeutics for COVID-19, as well as other indications.

In “Antibodies to Watch in a Pandemic”, Dr. Janice Reichert (The Antibody Society) provides an update on non-COVID-19 antibody therapeutics approved in the first half of 2020, and those that might be approved by the end of the year. She also discusses the ~ 130 biologics currently in development for COVID-19, which includes over 50 repurposed biologics and over 80 anti-SARS-CoV-2 biologics. Additionally, Dr. Thomas Schirrmann (Yumab) presents a case study of how to develop anti-SARS-CoV-2 antibodies in both academic and industrial settings.

Seminar Information
Seminar Date:
June 30, 2020
Register Now
In order to access this program after registering, a TAS account will be provided for you based on the information you have entered.

To access your account after your purchase, use the My Account links on the left hand side of this page to login using the information your provide here.
According to our records there is already a TAS account using the email address you have provided.

To continue with your registration please enter your account password. If you do not know your account password you can retrieve it here: Forgot Password?
First Name:
Last Name:
Email:
Confirm Email:
Product:
Streaming
The email address you have entered has an existing TAS account.

Please enter your password in the field below. Forgot Password?

Email:
Password:
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Antibodies to Watch in a Pandemic

The extraordinary scope and scale of the COVID-19 pandemic has elicited extraordinary responses world-wide. Organizations located across the globe have mobilized teams to research the SARS-CoV-2 virus and COVID-19, conduct clinical studies of repurposed biologics, and research and develop anti-SARS-CoV-2 biologics. Disruptions at companies and regulatory agencies, however, have raised concerns about the effects of the pandemic on possible approvals of non-COVID-19 antibody therapeutics.

 

In this webinar, Dr. Janice Reichert (The Antibody Society) provides an update on non-COVID-19 antibody therapeutics approved in the first half 2020, and those that might be approved by the end of the year. She also discusses the ~ 130 biologics currently in development for COVID-19, which includes over 50 repurposed biologics and over 80 anti-SARS-CoV-2 biologics.

 

Additionally, Dr. Thomas Schirrmann (YUMAB) presents a case study of an academic and industrial consortium for the fast-track development of a SARS-CoV-2 antibody therapy. He will highlight the challenges of discovering and developing an antibody drug during the present pandemic.

Speaker Information
Janice Reichert  [ view bio ]
Thomas Schirrmann  [ view bio ]
Individual topic purchase: Selected